Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271176 | 0.85 | GRM7 (0.41) | GRM7RBP4MEN1KMT2ACACNA2D1 | |
| SCHEMBL13701479 | 0.83 | GLS (0.42) | — | |
| SCHEMBL4283097 | 0.81 | GRM7 (0.44) | GRM7MEN1KMT2ACACNA2D1CACNB1 | |
| SCHEMBL4278872 | 0.74 | GRM7 (0.37) | GRM7RBP4MEN1KMT2ACACNA2D1 | |
| SCHEMBL4281028 | 0.74 | GRM7 (0.38) | GRM7MEN1KMT2ACACNA2D1CACNB1 | |
| SCHEMBL13701480 | 0.71 | OPRD1 (0.38) | MEN1KMT2A | |
| SCHEMBL20129640 | 0.70 | PARP1 (0.44) | MEN1KMT2A | |
| SCHEMBL4271679 | 0.69 | CACNA2D1 (0.65) | MEN1KMT2ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL4278651 | 0.69 | GPR119 (0.42) | MEN1KMT2A | |
| SCHEMBL4278436 | 0.68 | CYP3A4 (0.44) | MEN1KMT2ACACNA2D1CACNB1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | GRM7 747/4885RBP4 4325/4885MEN1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.